{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"39"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions;","groups":[{"description":"Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG000","title":"Phase I, All Histologies, Lenalidomide 15 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG001","title":"Phase I, All Histologies, Lenalidomide 20 mg"},{"description":"Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG002","title":"Phase I, All Histologies, Lenalidomide 25 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG003","title":"Phase II, Diffuse Large B-Cell Subtype"},{"description":"Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG004","title":"Phase II, Follicular Subtype"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG005","title":"Phase II, Lymphoma NOS"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only phase II patients were assessed for complete response.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Complete Response (Phase II)","type":"PRIMARY","unitOfMeasure":"Participants"}